Talphera TLPH
NASDAQ TLPH
$1.24 +0.02 (+1.64%)
At close: Sep 10, 2026 · 4:00 PM EDT

Talphera (TLPH) Liabilities from Discontinued Operations (2022 - 2026)

Talphera (TLPH) posted Liabilities from Discontinued Operations of $650000.0 for Q2 2026, little changed on a QoQ basis from $650000.0 in Q1 2026, and little changed year-over-year from $650000.0 in Q2 2025.

Analysis

Talphera (TLPH) Liabilities from Discontinued Operations (2022 - 2026) Analysis & Trends

Talphera has reported Liabilities from Discontinued Operations for 5 years, with the latest figure at $650000.0 in Q2 2026.

  • On a quarterly basis, Liabilities from Discontinued Operations changed 0.0% year-over-year to $650000.0 in Q2 2026; TTM through Jun 2026 was $650000.0, a 0.0% change from a year earlier, with the FY2025 full-year figure at $650000.0, down 10.1% from the prior year.
  • Liabilities from Discontinued Operations was $650000.0 for Q2 2026 at Talphera, roughly flat from $650000.0 in the prior quarter.
  • The five-year high for Liabilities from Discontinued Operations was $4.6 million in Q4 2022, with the low at $650000.0 in Q1 2025.
  • Average Liabilities from Discontinued Operations over 5 years is $1.2 million, with a median of $723000.0 recorded in 2024.
  • The sharpest annual moves came in 2023 and 2026: Liabilities from Discontinued Operations tumbled 84.18% in 2023, then changed 0.0% in 2026.
  • Over 5 years, Liabilities from Discontinued Operations stood at $4.6 million in 2022, then sank by 84.18% to $731000.0 in 2023, then declined by 1.09% to $723000.0 in 2024, then fell by 10.1% to $650000.0 in 2025, then changed by 0.0% to $650000.0 in 2026.
  • The last three Liabilities from Discontinued Operations figures came in at $650000.0 (Q2 2026), $650000.0 (Q1 2026), and $650000.0 (Q4 2025), per Business Quant data.
Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Amgen 206.44 Bn 192.45 Bn 7.24 Bn
2 Gilead Sciences 179.97 Bn 176.79 Bn 6.22 Bn
3 Vertex Pharmaceuticals 130.57 Bn 122.72 Bn 2.84 Bn
4 Regeneron Pharmaceuticals 81.63 Bn 73.63 Bn 3.93 Bn
5 Argenx Se 60.34 Bn 55.16 Bn 1.37 Bn
6 Moderna 54.37 Bn 49.23 Bn 52.00 Mn
7 Alnylam Pharmaceuticals 33.07 Bn 29.76 Bn 992.69 Mn
8 Biogen 31.84 Bn 30.55 Bn 1.96 Bn
9 Roivant Sciences 29.49 Bn 29.49 Bn 1.16 Mn
10 Talphera 92.90 Mn 92.90 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2026 650,000.00
Mar 31, 2026 650,000.00
Dec 31, 2025 650,000.00
Sep 30, 2025 650,000.00
Jun 30, 2025 650,000.00
Mar 31, 2025 650,000.00
Dec 31, 2024 723,000.00
Sep 30, 2024 723,000.00
Jun 30, 2024 723,000.00
Mar 31, 2024 730,000.00
Dec 31, 2023 731,000.00
Sep 30, 2023 756,000.00
Jun 30, 2023 1.16 Mn
Mar 31, 2023 3.28 Mn
Dec 31, 2022 4.62 Mn